| http://purl.uniprot.org/citations/35325069 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/35325069 | http://www.w3.org/2000/01/rdf-schema#comment | "IL-36 has been implicated in the pathogenesis of spondyloarthropathies (SpA) like psoriasis and inflammatory bowel disease. Enthesitis-related arthritis (ERA) category of juvenile idiopathic arthritis is a form of juvenile SpA, however, no data is available on the role of IL-36 in this disease. IL-36α, β, γ and IL-36R mRNA expression in blood and synovial fluid mononuclear cells and IL-36α, γ, IL-36Ra, IL-6, and IL-17 levels were measured in serum and synovial fluid (SF). IL-36γ production by fibroblast-like synoviocytes (FLS) upon stimulation with pro-inflammatory cytokines and its effect on FLS were also studied. mRNA levels of IL-36α, IL-36γ, and IL-36R were increased in PBMCs of ERA patients as compared to healthy controls however only IL-36γ was measurable in the serum of one-third of patients. In SFMCs, all four mRNA were detectable but were lower than RA patients. SF IL-36γ levels correlated with disease activity score (r = 0.51, P < 0.0001), SF IL-6 (r = 0.4, P = 0.0063) and IL-17 levels (r = 0.57, P = 0.0018). Pro-inflammatory cytokines increased the expression of IL-36γ and IL-6 in FLS cultures. SFs from five ERA patients also increased expressions of IL-36γ and IL-6 in FLS which could be blocked by using IL-36Ra. This suggests that pro-inflammatory cytokines aid in the upregulation of IL-36γ which in turn may upregulate the expression of IL-6. This might lead to a positive feedback loop of inflammation in ERA. Association of SF levels of IL-36γ with disease activity further supports this possibility. IL-36Ra based therapy may have a role in ERA."xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.org/dc/terms/identifier | "doi:10.1093/cei/uxac027"xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/author | "Aggarwal A."xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/author | "Majumder S."xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/author | "Guleria S."xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/date | "2022"xsd:gYear |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/name | "Clin Exp Immunol"xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/pages | "212-219"xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/title | "IL-36gamma in enthesitis-related juvenile idiopathic arthritis and its association with disease activity."xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://purl.uniprot.org/core/volume | "208"xsd:string |
| http://purl.uniprot.org/citations/35325069 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/35325069 |
| http://purl.uniprot.org/citations/35325069 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/35325069 |
| http://purl.uniprot.org/uniprot/#_Q9NZH8-mappedCitation-35325069 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35325069 |
| http://purl.uniprot.org/uniprot/Q9NZH8 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/35325069 |